Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

Phase 1/2 Completed 14 enrolled Nivalis Therapeutics, Inc.

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.

Timeline

Start: 2011-03
Primary completion: 2011-11
Completion: 2011-12

Outcome

Missed primary endpoint

paper This was a negative trial as it failed to reach its primary endpoint PMID 29642282 ↗

Publications

Que LG, Yang Z, Lugogo NL, Katial RK, Shoemaker SA, Troha JM, Rodman DM, Tighe RM, Kraft M. Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. Immun Inflamm Dis. 2018 Jun;6(2):322-331. doi: 10.1002/iid3.220. Epub 2018 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N6022	Small molecule	5 mg	Intravenous